Who are TDaP-IPV vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 23vPPV+TIV, sIPV+DTaP+HepA, Boostrix IPV infant whole Pertussis, Boostrix ® Polio, sIPV+DTaP+MMR, hepatitis A vaccine, DTaP, PCV10.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tdap-ipv-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TDaP-IPV vaccine — Competitive Intelligence Brief

TDaP-IPV vaccine (TDaP-IPV vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: combination vaccine. Area: Immunology.

marketed combination vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

TDaP-IPV vaccine (TDaP-IPV vaccine) — Radboud University Medical Center. TDaP-IPV is a combination vaccine that stimulates the immune system to produce antibodies against tetanus, diphtheria, pertussis, and poliovirus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
TDaP-IPV vaccine TARGET	TDaP-IPV vaccine	Radboud University Medical Center	marketed	combination vaccine
23vPPV+TIV	23vPPV+TIV	Jiangsu Province Centers for Disease Control and Prevention	marketed	Combination vaccine
sIPV+DTaP+HepA	sIPV+DTaP+HepA	China National Biotec Group Company Limited	marketed	Combination vaccine
Boostrix IPV infant whole Pertussis	Boostrix IPV infant whole Pertussis	London School of Hygiene and Tropical Medicine	marketed	Combination vaccine
Boostrix ® Polio	Boostrix ® Polio	GlaxoSmithKline	marketed	Combination vaccine
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine
hepatitis A vaccine, DTaP, PCV10	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (combination vaccine class)

GlaxoSmithKline · 2 drugs in this class
KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TDaP-IPV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/tdap-ipv-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab